GlassScriptPhysician profile
Aman K Kakkar
NPI 1801833173
$6,905.53
in general payments reported to CMS, 2019-2025
49 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $629 · 2021: $1,368 · 2022: $1,143 · 2023: $782 · 2024: $822 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596 · Entertainment: $66.67 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.63 |
| Entertainment | $66.67 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $822.00 | 2019-2024 | Xarelto |
| Pfizer INC. | $701.73 | 2019-2025 | |
| Biotronik INC. | $556.29 | 2022-2024 | Orsiro Mission, Nhancer Rx |
| Boston Scientific Corporation | $553.23 | 2019-2025 | Watchman Flx, Watchman Access System, General - Therapies |
| Novartis Pharmaceuticals Corporation | $504.99 | 2020-2025 | |
| Cvrx, INC. | $320.30 | 2023-2025 | Barostim Neo System |
| Medtronic, INC. | $293.91 | 2021-2024 | Reveal Linq |
| Abbott Laboratories | $278.64 | 2019-2024 | Mitraclip, Gallant |
| Novo Nordisk INC | $249.76 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abiomed | $228.56 | 2019-2025 | Impella |
| Amgen INC. | $180.53 | 2019-2025 | Repatha, Repatha |
| Atricure, INC. | $131.75 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $131.55 | 2019-2024 | Opsumit |
| Esperion Therapeutics, INC. | $128.70 | 2020-2023 | Nexletol |
| Inspire Medical Systems, INC. | $120.69 | 2023-2025 | Inspire |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Kakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.